Cytek Biosciences, Inc. provided revenue guidance for the full year 2022. The company expects full year 2022 revenue to be closer to the high end of the range of $160 million to $168 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.61 USD | -1.23% |
|
-9.22% | -38.49% |
06-12 | Cytek Biosciences to Seek M&A | CI |
06-12 | Transcript : Cytek Biosciences, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 09:20 AM |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.49% | 736M | |
+7.23% | 217B | |
+11.31% | 191B | |
+28.94% | 154B | |
+32.00% | 112B | |
-0.46% | 62.84B | |
+16.09% | 53.34B | |
+0.94% | 48.83B | |
-2.97% | 39.36B | |
+1.23% | 35.73B |
- Stock Market
- Equities
- CTKB Stock
- News Cytek Biosciences, Inc.
- Cytek Biosciences, Inc. Provides Revenue Guidance for the Full Year 2022